L&G Pharma Breakthrough UCITS ETF - USD Share Price

ETF

Market Closed - Swiss Exchange Other stock markets 09:25:01 31/05/2024 am IST			5-day change	1st Jan Change
9.379 ^USD	+0.63%		-2.37%	-10.63%

2018

Duration

Period

Style

The L&G Pharma Breakthrough UCITS ETF (the 'ETF') aims to track the performance of the Solactive Pharma Breakthrough Value Index (the 'Index').

Name	Price	Change	5d. change	1st Jan change	Weight
SWEDISH ORPHAN BIOVITRUM AB	282.4 SEK	+1.66%	+0.79%	+5.77%	4.51%
CHUGAI PHARMACEUTICAL CO., LTD	4,781 JPY	+1.90%	+0.70%	-10.50%	4.07%
IONIS PHARMACEUTICALS, INC.	37.57 USD	+2.79%	+0.78%	-25.74%	4.01%
PHARMA MAR, S.A.	37.4 EUR	+0.43%	+3.83%	-8.96%	3.95%
INNOVENT BIOLOGICS, INC.	35.2 HKD	-0.14%	-1.95%	-17.66%	3.82%
VERTEX PHARMACEUTICALS INCORPORATED	455.3 USD	+2.77%	-0.35%	+11.91%	3.73%
SINO BIOPHARMACEUTICAL LIMITED	2.84 HKD	+1.43%	-1.05%	-18.16%	3.67%
ZAI LAB LIMITED	17.78 USD	-2.25%	-0.78%	-34.94%	3.36%
BIOMARIN PHARMACEUTICAL INC.	75.07 USD	+0.79%	-0.60%	-22.14%	3.36%
INNOCARE PHARMA LIMITED	4.32 HKD	+0.47%	-5.47%	-37.30%	3.34%

Franklin Templeton's spot ether ETF sets fees at 0.19%	31/05	RE
US equity funds hit by outflows on rising yields, rates uncertainty	31/05	RE
Global equity funds record first outflows in five weeks amid rising U.S. yields	31/05	RE
First Trust Exchange Traded Fund IV - First Trust Enhanced Short Maturity ETF Declares Monthly Distribution, Payable on June 4, 2024	31/05	CI
Directa SIM signs deal with Fidelity International to distribute ETFs	30/05	AN
Eq8 Dow Jones Us Titans 50 Etf Announces Retirement of Encik Imran Devindran Bin Abdullah as Independent and Non Executive	30/05	CI
Fidelity won't levy proposed fees on purchases from boutique ETF firms, sources say	30/05	RE
Kenanga Investment Bank Berhad - Kenanga Klci Daily 2X Leveraged ETF Announces Retirement of Encik Imran Devindran Bin Abdullah as Independent and Non Executive Director	30/05	CI

In partnership with

Other stock markets

Delayed Quote Swiss Exchange

Last update May 31, 2024 at 09:25 am IST

	IE00BF0H7608
Total Expense Ratio	0.49%
Asset Class	Equities
Sector	No restriction
Size	No restriction
Currency	USD
Provider	LGIM
Underlying	Solactive Pharma Breakthrough Value NTR Index - USD

Retail investor